Proteo, Minapharm Ink License Agreement for Elafin

Egyptian Minapharm Pharmaceuticals and German biotech company Proteo announced Rhein Minapharm, a subsidiary of Minapharm, and Proteo have entered into a license agreement for the clinical development, production and marketing of Elafin in several Middle Eastern and African countries.

Minapharm and Proteo said that Elafin is a treatment for inflammatory lung diseases or severe reperfusion injuries occurring after heart attacks, serious injuries and organ transplantations.

Rhein Minapharm said it will market Elafin in these regions, and Proteo said it will receive an upfront payment, milestone payments and royalties on net product sales.

Minapharm added that it will take over the funding of clinical research activities for the designated region.

According to the companies, the tolerability of Elafin in human subjects was  demonstrated in a Phase I clinical single dose-escalating study.